Physicochemical Excipient-Container Interactions in Prefilled Syringes and Their Impact on Syringe Functionality

References

1. 1.↵
   1. Shi G. H.,
   2. Gopalrathnam G.,
   3. Shinkle S. L.,
   4. Dong X.,
   5. Hofer J. D.,
   6. Jensen E. C.,
   7. Rajagopalan N.

   Impact of Drug Formulation Variables on Silicone Oil Structure and Functionality of Prefilled Syringe System. PDA J. Pharm. Sci. Technol. 2018, 72 (1), 50–61.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Bittner B.,
   2. Richter W.,
   3. Schmidt J.

   Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. BioDrugs 2018, 32 (5), 425–440.

   OpenUrl
3. 3.↵
   1. Anderson K. C.,
   2. Landgren O.,
   3. Arend R. C.,
   4. Chou J.,
   5. Jacobs I. A.

   Humanistic and Economic Impact of Subcutaneous versus Intravenous Administration of Oncology Biologics. Future Oncol. 2019, 15 (28), 3267–3281.

   OpenUrl
4. 4.↵
   1. Shire S. J.,
   2. Shahrokh Z.,
   3. Liu J.

   Challenges in the Development of High Protein Concentration Formulations. J. Pharm. Sci. 2004, 93 (6), 1390–1402.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Dounce S. M.

   The Changing Paradigm in Primary Packaging of Therapeutic Proteins. Pharm. Commerce [Online] 2017. https://pharmaceuticalcommerce.com/manufacturing-and-packaging/changing-paradigm-primary-packaging-therapeutic-proteins/ (accessed Nov 10, 2020)
6. 6.↵
   1. Schoenknecht T.,
   2. Romacker M.

   Prefilled Syringes: Why New Developments Are Important in Injectable Delivery Today. In Prefilled Syringes: Innovations that Meet the Growing Demand; ONDrugDelivery Ltd: East Sussex, UK, 2005; pp 9–11.
7. 7.↵
   1. Overcashier D. E.,
   2. Chan E. K.,
   3. Hsu C. C.

   Technical Considerations in the Development of Prefilled Syringes for Protein Products. Am. Pharm. Rev. 2004, 9 (7), 77–83.

   OpenUrl
8. 8.↵
   1. Bee J. S.,
   2. Frey V. V.,
   3. Javed U.,
   4. Chung J.,
   5. Corcoran M. L.,
   6. Roussel P. S.,
   7. Krause S. O.,
   8. Cash P. W.,
   9. Bishop S. M.,
   10. Dimitrova M. N.

   Characterization of the Initial Level and Migration of Silicone Oil Lubricant in Empty Prefilled Syringes for Biologics Using Infrared Spectroscopy. PDA J. Pharm. Sci. Technol. 2014, 68 (5), 494–503.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Dixit N.,
   2. Maloney K. M.,
   3. Kalonia D. S.

   Effect of Processing Parameters on the Physical Stability of Silicone Coatings. AAPS PharmSciTech 2012, 13 (4), 1116–1119. Dec,

   OpenUrlPubMed
10. 10.↵
    1. Bee J. S.,
    2. Randolph T. W.,
    3. Carpenter J. F.,
    4. Bishop S. M.,
    5. Dimitrova M. N.

    Effects of Surfaces and Leachables on the Stability of Biopharmaceuticals. J. Pharm. Sci. 2011, 100 (10), 4158–4170.

    OpenUrl
11. 11.↵
    1. Gerhardt A.,
    2. Mcgraw N. R.,
    3. Schwartz D. K.,
    4. Bee J. S.,
    5. Carpenter J. F.,
    6. Randolph T. W.

    Protein Aggregation and Particle Formation in Prefilled Glass Syringes. J. Pharm. Sci. 2014, 103 (6), 1601–1612.

    OpenUrl
12. 12.↵
    1. Mehta S. B.,
    2. Lewus R.,
    3. Bee J. S.,
    4. Randolph T. W.,
    5. Carpenter J. F.

    Gelation of a Monoclonal Antibody at the Silicone Oil–Water Interface and Subsequent Rupture of the Interfacial Gel Results in Aggregation and Particle Formation. J. Pharm. Sci. 2015, 104 (4), 1282–1290.

    OpenUrl
13. 13.↵
    1. Richard C. A.,
    2. Wang T.,
    3. Clark S. L.

    Using First Principles to Link Silicone Oil/Formulation Interfacial Tension with Syringe Functionality in Pre-Filled Syringes Systems. J. Pharm. Sci. 2020, 109 (10), 3006–3012.

    OpenUrl
14. 14.↵
    1. Wang T.,
    2. Richard C. A.,
    3. Dong X.,
    4. Shi G. H.

    Impact of Surfactants on the Functionality of Prefilled Syringes. J. Pharm. Sci. 2020, 109 (11), 3413–3422.

    OpenUrl
15. 15.↵
    Hansen Solubility Parameters—The Double Sphere. https://www.hansen-solubility.com/HSP-examples/double-sphere.php (accessed May 15, 2020).
16. 16.↵
    1. Hansen C. M.

    Hansen Solubility Parameters: A User’s Handbook, 2nd ed.; CRC Press/Taylor & Francis Group: Boca Raton, FL, 2007; p 6.
17. 17.↵
    HSPiP Software and 10K Chemical Database. Version 5.0.04. https://www.hansen-solubility.com/HSPiP (accessed May 15, 2020)
18. 18.↵
    1. Abbott S.,
    2. Hansen C. M.,
    3. Yamamoto H.,
    4. Valpey R. S. III.

    , Insoluble Solubility Parameters (HSP for Pigment Surfaces). In Hansen Solubility Parameters in Practice, 5th ed.; Hansen-Solubility.com; p 72. https://pirika.com/ENG/HSP/E-Book/Chap10.html.
19. 19.↵
    1. Gopalrathnam G.,
    2. Sharma A. N.,
    3. Dodd S. W.,
    4. Huang L.

    Impact of Stainless-Steel Exposure on the Oxidation of Polysorbate 80 in Histidine Placebo and Active Monoclonal Antibody Formulation. PDA J. Pharm. Sci. Technol. 2018, 72 (2), 163–175.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Chung H. H.,
    2. Zhou C.,
    3. Khor H. K.,
    4. Qiu J.

    Direct Determination of Residual Pluronic F-68 in in-Process Samples from Monoclonal Antibody Preparations by High Performance Liquid. J. Chromatogr. A 2011, 1218 (15), 2106–2113.

    OpenUrlPubMed
21. 21.↵
    1. Fang L.,
    2. Shi G. H.,
    3. Richard C. A.,
    4. Dong X.,
    5. Thomas J. C.,
    6. Victor M. C.,
    7. Wang T.,
    8. Shinkle S.,
    9. Zhao C.

    Mechanisms of Drug Formulation Impact on Prefilled Syringe Functionality and Autoinjector Performance. PDA J Pharm Sci Technol, 2020, 74 (6), 674–687.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Poullain-Termeau S.,
    2. Crauste-Manciet S.,
    3. Brossard D.,
    4. Muhamed S.,
    5. Nicolaos G.,
    6. Farinotti R.,
    7. Barthélémy C.,
    8. Robert H.,
    9. Odou P.

    Effect of Oil-in-Water Submicron Emulsion Surface Charge on Oral Absorption of a Poorly Water-Soluble Drug in Rats. Drug Delivery 2008, 15 (8), 503–514.

    OpenUrlPubMed
23. 23.↵
    1. Kishore R. S.,
    2. Pappenberger A.,
    3. Dauphin I. B.,
    4. Ross A.,
    5. Buergi B.,
    6. Staempfli A.,
    7. Mahler H. C.

    Degradation of Polysorbates 20 and 80: Studies on Thermal Autoxidation and Hydrolysis. J. Pharm. Sci. 2011, 100 (2), 721–731

    OpenUrlPubMed
24. 24.↵
    1. Borisov O. V.,
    2. Ji J. A.,
    3. Wang Y. J.

    Oxidative Degradation of Polysorbate Surfactants Studied by Liquid Chromatography-Mass Spectrometry. J. Pharm. Sci. 2015, 104 (3), 1005–1018.

    OpenUrlPubMed
25. 25.↵
    1. Kranz W.,
    2. Wuchner K.,
    3. Corradini E.,
    4. Berger M.,
    5. Hawe A.

    Factors Influencing Polysorbate's Sensitivity against Enzymatic Hydrolysis and Oxidative Degradation. J. Pharm. Sci. 2019, 108 (6), 2022–2032.

    OpenUrl
26. 26.↵
    1. Doyle Drbohlav L. M.,
    2. Sharma A. N.,
    3. Gopalrathnam G.,
    4. Huang L.,
    5. Bradley S.

    A Mechanistic Understanding of Polysorbate 80 Oxidation in Histidine and Citrate Buffer Systems—Part 2. PDA J. Pharm. Sci. Technol. 2019, 73 (4), 320–330.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Larson N. R.,
    2. Wei Y.,
    3. Prajapati I.,
    4. Chakraborty A.,
    5. Peters B.,
    6. Kalonia C.,
    7. Hudak S.,
    8. Choudhary S.,
    9. Esfandiary R.,
    10. Dhar P.,
    11. Schöneich C.,
    12. Middaugh C. R.

    Comparison of Polysorbate 80 Hydrolysis and Oxidation on the Aggregation of a Monoclonal Antibody. J. Pharm. Sci. 2020, 109 (1), 633–639.

    OpenUrl
28. 28.↵
    1. Wang T.,
    2. Markham A.,
    3. Thomas S. J.,
    4. Wang N.,
    5. Huang L.,
    6. Clemens M.,
    7. Rajagopalan N.

    Solution Stability of Poloxamer 188 under Stress Conditions. J Pharm. Sci 2019, 108 (3), 1264–1271.

    OpenUrl
29. 29.↵
    1. Labrenz S. R.

    Ester Hydrolysis of Polysorbate 80 in mAb Drug Product: Evidence in Support of the Hypothesized Risk after the Observation of Visible Particulate in mAb Formulations. J. Pharm. Sci. 2014, 103 (8), 2268–2277.

    OpenUrlPubMed
30. 30.↵
    1. McShan A. C.,
    2. Kei P.,
    3. Ji J. A.,
    4. Kim D. C.,
    5. Wang Y. J.

    Hydrolysis of Polysorbate 20 and 80 by a Range of Carboxylester Hydrolases. PDA J. Pharm. Sci. Technol. 2016, 70 (4), 332–345.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Hall T.,
    2. Sandefur S. L.,
    3. Frye C. C.,
    4. Tuley T. L.,
    5. Huang L.

    Polysorbates 20 and 80 Degradation by Group XV Lysosomal Phospholipase A2 Isomer X1 in Monoclonal Antibody Formulations. J. Pharm. Sci. 2016, 105 (5), 1633–1642.

    OpenUrl
32. 32.↵
    1. Dixit N.,
    2. Salamat-Miller N.,
    3. Salinas P. A.,
    4. Taylor K. D.,
    5. Basu S. K.

    Residual Host Cell Protein Promotes Polysorbate 20 Degradation in a Sulfatase Drug Product Leading to Free Fatty Acid Particles. J. Pharm. Sci. 2016, 105 (5), 1657–1666.

    OpenUrl
33. 33.
    1. Tomlinson A.,
    2. Demeule B.,
    3. Lin B.,
    4. Yadav S.

    Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism. Mol. Pharmaceutics 2015, 12 (11), 3805–3815.

    OpenUrl